2014年全国职称英语考试 卫生类B级 阅读与完形填空押题【孙、王、李三个王牌老师综合而来】 .doc

once daily pill could simplify hiv treatmentbeistol-myers squibb and gilead sciences have combined many hiv drugs into a single pill. sometimes the best medicine is moer than one kind of medicine. maiaria,tuberculosis and hiv/aids, for example, are all treated with combinations of drugs. but that can mean a lot of pills to take. it would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .now, two companies say they have done that foe people just starting treatment for hiv, the virus that causes aids. the companies are bristol-myers squibb and gilead sciences. they have developed a single pill that combines three drugs currently on the market . bristol-myers squibb sells one of them under the name of sustiva. gilead combined the others, emtriva and viread, into a single pill in two thousand four.combining drugs involeves more than technical issues. it also involves issues of competition if the drugs are made by different companies. the new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of hiv. in january the new england journal of medicine published a study of the new pill . researchers compared its effectiveness to that of the widely used combination of sustiva and combivir. combivir contains two drugs, azt and 3tc. the researchers say that after one year of treatment, the new pill suppressed hiv levels in more patients and with fewer side effects. gilead paid for the study. professor joel gallant at the johns hopkins school of medicine in baltimore, maryland, led the reaearch . he is paid adviser to gilead ang bristol-meyers squibb as well as the maker of combivir, glaxo smith kline. glaxo smith kline reacted to the findings by saying that a single study is of limited value. it says the effectiveness of combivir has been shown in each of more the fifty studies.the price of the new once-daily pill has not beet announced. but gilead ang bristol-myers squibb say they will provide it at reduced cost to developing countries. they plan in the next few months to ask the united states food and drug administration to approve the new pill. there are limits to who could take it because of the different drugs it contains.for example pregnant women are told not to take sustiva because of the risk of birth disorders.experts say more than forty million people around the world are living with hiv.once daily pill could simplify hiv treatmentbeistol-myers squibb and gilead sciences have combined many hiv drugs into a single pill. sometimes the best medicine is moer than one kind of medicine. maiaria,tuberculosis and hiv/aids, for example, are all treated with combinations of drugs. but that can mean a lot of pills to take. it would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .now, two companies say they have done that foe people just starting treatment for hiv, the virus that causes aids. the companies are bristol-myers squibb and gilead sciences. they have developed a single pill that combines three drugs currently on the market . bristol-myers squibb sells one of them under the name of sustiva. gilead combined the others, emtriva and viread, into a single pill in two thousand four.combining drugs involeves more than technical issues. it also involves issues of competition if the drugs are made by different companies. the new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of hiv. in january the new england journal of medicine published a study of the new pill . researchers compared its effectiveness to that of the widely used combination of sustiva and combivir. combivir contains two drugs, azt and 3tc. the researchers say that after one year of treatment, the new pill suppressed hiv levels in more patients and with fewer side effects. gilead paid for the study. professor joel gallant at the johns hopkins school of medicine in baltimore, maryland, led the reaearch . he is paid adviser to gilead ang bristol-meyers squibb as well as the maker of combivir, glaxo smith kline. glaxo smith kline reacted to the findings by saying that a single study is of limited value. it says the effectiveness of combivir has been shown in each of more the fifty studies.the price of the new once-daily pill has not beet announced. but gilead ang bristol-myers squibb say they will provide it at reduced cost to developing countries. they plan in the next few months to ask the united states food and drug administration to approve the new pill. there are limits to who could take it because of the different drugs it contains.for example pregnant women are told not to take sustiva because of the risk of birth disorders.experts say more than forty million people around the world are living with hiv.once daily pill could simplify hiv treatmentbeistol-myers squibb and gilead sciences have combined many hiv drugs into a single pill. sometimes the best medicine is moer than one kind of medicine. maiaria,tuberculosis and hiv/aids, for example, are all treated with combinations of drugs. but that can mean a lot of pills to take. it would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .now, two companies say they have done that foe people just starting treatment for hiv, the virus that causes aids. the companies are bristol-myers squibb and gilead sciences. they have developed a single pill that combines three drugs currently on the market . bristol-myers squibb sells one of them under the name of sustiva. gilead combined the others, emtriva and viread, into a single pill in two thousand four.combining drugs involeves more than technical issues. it also involves issues of competition if the drugs are made by different companies. the new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of hiv. in january the new england journal of medicine published a study of the new pill . researchers compared its effectiveness to that of the widely used combination of sustiva and combivir. combivir contains two drugs, azt and 3tc. the researchers say that after one year of treatment, the new pill suppressed hiv levels in more patients and with fewer side effects. gilead paid for the study. professor joel gallant at the johns hopkins school of medicine in baltimore, maryland, led the reaearch . he is paid adviser to gilead ang bristol-meyers squibb as well as the maker of combivir, glaxo smith kline. glaxo smith kline reacted to the findings by saying that a single study is of limited value. it says the effectiveness of combivir has been shown in each of more the fifty studies.the price of the new once-daily pill has not beet announced. but gilead ang bristol-myers squibb say they will provide it at reduced cost to developing countries. they plan in the next few months to ask the united states food and drug administration to approve the new pill. there are limits to who could take it because of the different drugs it contains.for example pregnant women are told not to take sustiva because of the risk of birth disorders.experts say more than forty million people around the world are living with hiv.once daily pill could simplify hiv treatmentbeistol-myers squibb and gilead sciences have combined many hiv drugs into a single pill. sometimes the best medicine is moer than one kind of medicine. maiaria,tuberculosis and hiv/aids, for example, are all treated with combinations of drugs. but that can mean a lot of pills to take. it would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .now, two companies say they have done that foe people just starting treatment for hiv, the virus that causes aids. the companies are bristol-myers squibb and gilead sciences. they have developed a single pill that combines three drugs currently on the market . bristol-myers squibb sells one of them under the name of sustiva. gilead combined the others, emtriva and viread, into a single pill in two thousand four.combining drugs involeves more than technical issues. it also involves issues of competition if the drugs are made by different companies. the new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of hiv. in january the new england journal of medicine published a study of the new pill . researchers compared its effectiveness to that of the widely used combination of sustiva and combivir. combivir contains two drugs, azt and 3tc. the researchers say that after one year of treatment, the new pill suppressed hiv levels in more patients and with fewer side effects. gilead paid for the study. professor joel gallant at the johns hopkins school of medicine in baltimore, maryland, led the reaearch . he is paid adviser to gilead ang bristol-meyers squibb as well as the maker of combivir, glaxo smith kline. glaxo smith kline reacted to the findings by saying that a single study is of limited value. it says the effectiveness of combivir has been shown in each of more the fifty studies.the price of the new once-daily pill has not beet announced. but gilead ang bristol-myers squibb say they will provide it at reduced cost to developing countries. they plan in the next few months to ask the united states food and drug administration to approve the new pill. there are limits to who could take it because of the different drugs it contains.for example pregnant women are told not to take sustiva because of the risk of birth disorders.experts say more than forty million people around the world are living with hiv.the case of the disappearing fingerprints one useful anti-cancer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.losing them could become troublesome.a case released online in a letter by annals of oncology indicates how big a problem of losing. eng-huat tan,a singapore-based medical doctor describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.after three years on the drug,the patient decided to visit u.s. relatives last decembr.but he was stopped by u.s. customs officials for 4 hours after entering the country when those officials couldnt get fingerprints from the man.there were no distinctive swirly marks appearing from his index finger. u.s.customs has been fingerprinting incoming foreign visitors for years,tan says.theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and potential criminals that our federal guardians have been tasked with keeping out of the country,unfortunately,for the singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.hence,no fingerprints. “it is uncertain when fingerprint loss will begin to take place in patients who are taking capecitabine,” tan points out. so he cautions any physicians who prescribe the drug to provide their patients with a doctors note pointing out that their medicine may cause fingerprints to disappear. eventually,the singapore traveler made it into the united states. i guess the name on his passport didnt raise any red flags.but hes also now got the explanatory doctors note-and wont leave home without it. by the way,maybe the food and drug administration,which approved use of the drug 11 years ago,should consider updating its list of side effects associated with this medicine.the current list does note that patients may experience vomiting,stomach pain and some other side effects. but no where does it mention the potential for loss of fingerprints.the case of the disappearing fingerprints one useful anti-cancer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.losing them could become troublesome.a case released online in a letter by annals of oncology indicates how big a problem of losing. eng-huat tan,a singapore-based medical doctor describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.after three years on the drug,the patient decided to visit u.s. relatives last decembr.but he was stopped by u.s. customs officials for 4 hours after entering the country when those officials couldnt get fingerprints from the man.there were no distinctive swirly marks appearing from his index finger. u.s.customs has been fingerprinting incoming foreign visitors for years,tan says.theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and potential criminals that our federal guardians have been tasked with keeping out of the country,unfortunately,for the singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.hence,no fingerprints. “it is uncertain when fingerprint loss will begin to take place in patients who are taking capecitabine,” tan points out. so he cautions any physicians who prescribe the drug to provide their patients with a doctors note pointing out that their medicine may cause fingerprints to disappear. eventually,the singapore traveler made it into the united states. i guess the name on his passport didnt raise any red flags.but hes also now got the explanatory doctors note-and wont leave home without it. by the way,maybe the food and drug administration,which approved use of the drug 11 years ago,should consider updating its list of side effects associated with this medicine.the current list does note that patients may experience vomiting,stomach pain and some other side effects. but no where does it mention the potential for loss of fingerprints.the case of the disappearing fingerprints one useful anti-cancer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.losing them could become troublesome.a case released online in a letter by annals of oncology indicates how big a problem of losing. eng-huat tan,a singapore-based medical doctor describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.after three years on the drug,the patient decided to visit u.s. relatives last decembr.but he was stopped by u.s. customs officials for 4 hours after entering the country when those officials couldnt get fingerprints from the man.there were no distinctive swirly marks appearing from his index finger. u.s.customs has been fingerprinting incoming foreign visitors for years,tan says.theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and potential criminals that our federal guardians have been tasked with keeping out of the country,unfortunately,for the singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.hence,no fingerprints. “it is uncertain when fingerprint loss will begin to take place in patients who are taking capecitabine,” tan points out. so he cautions any physicians who prescribe the drug to provide their patients with a doctors note pointing out that their medicine may cause fingerprints to disappear. eventually,the singapore traveler made it into the united states. i guess the name on his passport didnt raise any red flags.but hes also now got the explanatory doctors note-and wont leave home without it. by the way,maybe the food and drug administration,which approved use of the drug 11 years ago,should consider updating its list of side effects associated with this medicine.the current list does note that patients may experience vomiting,stomach pain and some other side effects. but no where does it mention the potential for loss of fingerprints.the case of the disappearing fingerprints one useful anti-cancer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.losing them could become troublesome.a case released online in a letter by annals of oncology indicates how big a problem of losing. eng-huat tan,a singapore-based medical doctor describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.after three years on the drug,the patient decided to visit u.s. relatives last decembr.but he was stopped by u.s. customs officials for 4 hours after entering the country when those officials couldnt get fingerprints from the man.there were no distinctive swirly marks appearing from his index finger. u.s.customs has been fingerprinting incoming foreign visitors for years,tan says.theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and potential criminals that our federal guardians have been tasked with keeping out of the country,unfortunately,for the singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.hence,no fingerprints. “it is uncertain when fingerprint loss will begin to take place in patients who are taking capecitabine,” tan points out. so he cautions any physicians who prescribe the drug to provide their patients with a doctors note pointing out that their medicine may cause fingerprints to disappear. eventually,the singapore traveler made it into the united states. i guess the name on his passport didnt raise any red flags.but hes also now got the explanatory doctors note-and wont leave home without it. by the way,maybe the food and drug administration,which approved use of the drug 11 years ago,should consider updating its list of side ef